Yarrow Bioscience, Inc. (YARW)
| Market Cap | $159.82M-25.5% |
| Revenue (ttm) | n/a |
| Net Income | -$283.98M |
| EPS | n/a |
| Shares Out | 11.47M |
| PE Ratio | n/a |
| Forward PE | -8.44 |
| Dividend | n/a |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 264,641 |
| Open | $18.03 |
| Previous Close | $18.03 |
| Day's Range | $13.75 - $19.35 |
| 52-Week Range | $12.38 - $46.95 |
| Beta | 2.13 |
| Analysts | Strong Buy |
| Price Target | $57.33(+311.58%) |
| Earnings Date | n/a |
About YARW
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
$YARW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in YARW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by YARW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
YARW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New YARW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to YARW from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from YARW’s recent data — informational, not investment advice
What’s Behind the Score
News check: Yarrow successfully completed a $172.5M public offering with full underwriter option exercise, demonstrating strong investor demand and capital raising execution.
